103
Views
4
CrossRef citations to date
0
Altmetric
Special Report

Efficacy and tolerability of rizatriptan 10 mg compared with sumatriptan 100 mg: an evidence-based analysis

Pages 499-506 | Published online: 09 Jan 2014

References

  • Diener HC, Putzki N, Berlit P et al.Leitlinien für Diagnostik und Therapie in der Neurologie. Georg Thieme Verlag, Stuttgart, Germany (2005).
  • Lee Y, Conroy JA, Stepanavage ME et al. Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br. J. Clin. Pharmacol.47(4), 373–378 (1999).
  • Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med.346, 257–270 (2002).
  • Tfelt-Hansen P, Teall J, Rodriguez F et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache38(10), 748–755 (1998).
  • Goldstein J, Ryan R, Jiang K et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache38(10), 737–747 (1998).
  • Kolodny A, Polis A, Battisti WP, Johnson-Pratt L, Skobieranda F; Rizatriptan Protocol 052 Study Group. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia24, 540–546 (2004).
  • Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K. Comparison of rizatriptan 10 mg vs zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan–Zolmitriptan Study Group. Cephalalgia20(5), 455–461 (2000).
  • Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur. Neurol.42(3), 173–179 (1999).
  • Ng-Mak DS, Hu XH, Chen Y, Ma L, Solomon G. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. J. Clin. Pract.61, 1091–1111 (2007).
  • Pascual J, Bussone G, Hernandez JF et al. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg on migraine. Eur. Neurol.45, 275–283 (2001).
  • Ferrari MD, Roon KI, Lipton RB, Goadsky PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
  • Kramer MS, Matzura-Wolfe D, Polis A et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology51(3), 773–781 (1998).
  • Belsey JD. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J. Clin. Res.4, 105–125 (2003).
  • Bussone G, D’Amico D, McCarroll KA, Gerth W, Lines CR. Restoring migraine sufferers’ ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. Eur. Neurol.48, 172–177 (2002).
  • Belsey JD. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Curr. Med. Res. Opin.20, 659–669 (2004).
  • Pascual J, Fité B, López-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache42, 93–98 (2002).
  • Haag G. Migraine and quality of life – results of the MELT survey. Nervenheilkunde23, 297–300 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.